Core Management Team
Wang Zhong Founder
PhD from Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, with many years of research in synthetic chemistry, previously served as chief scientist for multiple multinational corporations including Pacific Biosciences, USA. 19th International Chemistry Olympiad (IChO) Silver Medal. Chinese Academy of Sciences Outstanding Doctoral Scholarship (Shanghai Institute of Organic Chemistry). Dean's Special Award (Chinese Academy of Sciences' highest award). US O1 visa for individuals with extraordinary ability. Developed a macrocyclic anti-tumor drug with a novel mechanism of action, which has entered preclinical evaluation. Participated in the research and development of BTK inhibitor anticancer drugs; the BTK anticancer drug was later acquired by AbbVie for 21 billion US dollars.
Cheng Xu Chief Operating Officer
Pharmaceutical preparations major, MBA. Successively worked at Zhejiang Langhua Pharmaceutical, Jiuzhou Pharmaceutical, Federal Pharmaceutical, Lantuo Pharmaceutical, Fangsheng Pharmaceutical (JayrWell), and Hefei Huana Biotechnology. During this period, served in multiple management positions including: Workshop Director, QA Supervisor, Foreign Trade Manager, Marketing Director, Operations Director, Executive Deputy General Manager, and Chairman's Assistant. Has 16 years of experience in the pharmaceutical industry, with rich experience in production, quality management, and sales.
Bao Yan, VP of R&D
School of Chemistry and Materials Science, University of Science and Technology of China
Doctoral research direction: organic synthesis methodology
During doctoral studies, published multiple research papers in internationally renowned journals such as Chemical Science, Chem Commun.
Completed R&D tasks for multiple projects, including nucleotide route development
Has in-depth research on patent technology and other aspects; applied for 5 patents during employment, 2 of which have been granted
YuGuodong Vice President of Production
Organic Chemistry Major Possesses extensive experience in process development and production of nucleoside and nucleotide products. Within 5 years, led the team to develop over 30 complex process routes, covering various compound types, primarily including nucleoside triphosphates (dNTP, NTP), phosphoramidites (DNA, RNA), and modified nucleosides. And successfully led the team to complete process validation and achieve production transformation.
J.P.Collman
Member of the National Academy of Sciences (US), made landmark contributions in inorganic chemistry, metal ion biochemistry, homogeneous catalysis, and transition metal organometallic chemistry. Ronald Breslow Award for Biomimetic Chemistry International Coordination Chemistry Award from the Japan Society of Coordination Chemistry Hans Fischer Award for Porphyrin Chemistry Alfred Bader Award in Bioinorganic or Bioorganic Chemistry from the American Chemical Society Pauling Award, American Chemical Society, Puget Sound and Oregon Sections Guggenheim Fellow, John Simon Guggenheim Memorial Foundation Member of the American Academy of Arts and Sciences
Zhang Wentao
Ph.D. at University of Wisconsin-Madison
Postdoc at University of California, Berkeley
Senior Director at Exelixis
Founder and President at Quintara Discovery
Founded Quintara Discovery, providing ADME analysis services to renowned pharmaceutical companies such as Pfizer and Gilead, and was later acquired by Frontage in June 2021.
Established multiple platforms using LC-MS and RapidFire-MS to provide high-quality, high-throughput pharmacological analysis services.
Established drug discovery technology platforms to efficiently identify and discover 15 compounds entering clinical development.
Jiang Huanfeng
Professor, South China University of Technology
Associate Dean, School of Chemistry and Chemical Engineering, South China University of Technology
Recipient of the 1st Youth Knowledge Innovation Award by the Chinese Chemical Society-BASF
Provincial Cultivation Object of Guangdong Province Higher Education 'Qian Baishi Project'
Recipient of the National Science Fund for Distinguished Young Scholars
National Cultivation Object of Guangdong Province Higher Education 'Qian Baishi Project'
Outstanding Teacher of Guangdong Province
Recipient of the 11th Guangdong Ding Ying Science and Technology Award
Recipient of the State Council Special Government Allowance
Fu Lei
Professor Fu Lei was previously employed by the School of Pharmacy, Shanghai Jiao Tong University, serving as the group leader for pharmaceutical chemistry projects. He also worked at Pharmacyclics Inc. (acquired by AbbVie Inc.) engaging in preclinical research on novel anti-tumor and cardiovascular disease MRI imaging diagnostics and chemical drugs, etc. He currently serves as Associate Editor for Bio-organic Chemistry journal, Editorial Board Member for 'China Pharmaceutical Industry Journal' and its English version 'Pharmaceutical Fronts', Member of the Pharmaceutical Chemistry Committee of Shanghai Pharmaceutical Society, Deputy Director of the Biomedical Informatics Branch of the China Pharmaceutical Biotechnology Association, Standing Committee Member of the IoT Medical Professional Committee of the China Non-Governmental Medical Institutions Association, etc. His main research areas include: design and synthesis of novel chemical drugs and their preclinical research in anti-tumor, diabetes, cardiovascular diseases, and chronic pain, etc.; research on drug production processes and related substances in pharmaceuticals; mechanisms of mitochondrial activity regulation and exploration of their clinical applications, etc.
Lin Hong
Ph.D. in Organic Chemistry, Brandeis University. Postdoctoral Fellow, Memorial Sloan-Kettering Cancer Center. During 15 years at GlaxoSmithKline, served as multiple project leaders in drug chemistry and virtual drug discovery groups in oncology, neuroscience, and regenerative medicine therapeutic areas. Senior Vice President, Ouanta Therapeutics. Executive Director and Head of Early Discovery at Prelude Therapeutics, PRMT5 Project Leader, delivering clinical candidates PRT543 and PRT811 within two years.
Zhang Aimin
UC Berkeley Haas School of Business, MBA; PhD, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences; Associate Director, CMC R&D, Bristol-Myers Squibb (BMS); Senior Scientist, MyoKardia; Senior Scientist, Pacific Biosciences; Drafted drug substance submission documents for BMS new drugs; Managed and coordinated domestic and international CRO/CDMO companies; Managed and coordinated the global production of commercial APIs, intermediates, and raw materials.
Wish to receive more updates from Allbiosyn
Stay up-to-date with the latest product releases, technology trends, and upcoming events.
Product Management
- All
- Product Management
- News Information
- Introduction Content
- Enterprise Outlets
- FAQ
- Corporate Video
- Corporate Album
Phone:+8618666985712
Email:info@allbiosyn.com
WeChat ID: 18666985712
Address: Building 1, 883-885 Pinggang Road, Lingang New Area, Shanghai
Copyright © 2025 Allbiosyn (Shanghai) Biotechnology Co., Ltd. All Rights Reserved.